spacer
home > ebr > spring 2009 > dispersions deliver results
PUBLICATIONS
European Biopharmaceutical Review

Dispersions Deliver Results

 

Low-solubility, high-permeability compounds make up nearly one-third of all active pharmaceutical ingredients (APIs) in early development. For many compounds in this class, oral absorption can be achieved by enhancing solubility using solubilisation technologies. This article is an overview of current options in solid form solubilisation technologies, including several novel platforms that are based on nanocrystals and drug/polymer solid amorphous dispersions. The platforms discussed are spray-dried dispersions (SDDs), nanoadsorbates and crystallised spray-dried dispersions (CSDDs). Strategies are described to guide rational selection of the optimum technology for solubility enhancement.

Poor oral bioavailability due to the low aqueous solubility of potential drug candidates is an increasingly common challenge facing the pharmaceutical industry (1). Nearly one-third of compounds in early development have poor bioavailability due to low solubility, representing a significant loss in economic and therapeutic opportunity (2). Although they may not fit the ‘rule of five’, many of these low-solubility compounds – which fall into Class II of the Biopharmaceutics Classification System (BCS) – have the potential to be safe and efficacious, so it is critical that further development is not halted by solubility limitations (3).

In response to this problem, multiple drug-delivery technologies have been advanced in an attempt to solubilise such molecules in order to enhance their oral bioavailability. Solubilisation technologies can improve oral absorption of BCS Class II compounds by:

  • Increasing dissolution rate
  • Increasing concentration of dissolved drug (above the equilibrium concentration of the solubility of bulk crystalline drug)
  • Maintaining the enhanced dissolved drug concentration

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
1
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Dr David T Vodak is a Senior Research Chemist and Group Leader at Bend Research Inc, a private research and development laboratory in Bend, Oregon. David holds a PhD in materials chemistry from the University of Michigan-Ann Arbor and a BA in Chemistry from Willamette University in Salem, Oregon. After completing his post-doctoral work at the Scripps Research Institute in La Jolla, California, David joined Bend Research Inc, where he has worked on novel technology development. His areas of expertise are the research and development of novel pharmaceutical drug-delivery systems for the delivery of low-solubility compounds.

Dr Dwayne T Friesen is the Vice President of Research at Bend Research Inc. Dwayne holds a PhD in physical chemistry from Oregon State University in Corvallis, Oregon, and a BS in Chemistry from California State College – Bakersfield. He holds 44 US patents and has 15 scientific publications. Dwayne directs the research and development for novel drug-delivery systems and pharmaceutical formulations.

spacer
David T Vodak
spacer
spacer
spacer
Dwayne T Friesen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Automated testing of pharmaceutical packaging

Test-result reproducibility and traceability are essential when testing pharmaceutical packaging and medical products. Zwick has developed a robotic testing system for automated testing applications ranging from childproof bottles (withpress-and-turn caps) to auto-injectors and insulin pens; tests on these include determination of the release force. As well as increasing specimen throughput and reducing per-specimen costs, automation reduces operator influence, while releasing laboratory staff for more demanding activities in line with their skills and qualifications.
More info >>

White Papers

Contemporary Issues in Comparator Trial Supply

Clinigen CTS

As trial design and execution becomes ever-more complex, initiatives to adapt, increase efficiency and control costs without compromising quality become paramount. Here, Clinigen CTS covers the broad issues and summarises the responses our industry is making in this increasingly demanding landscape.
More info >>

 
Industry Events

Cell Therapy Manufacturing & Gene Therapy Congress

4-6 December 2018, RAI, Amsterdam

Bringing together 300+ leaders and key influencers from pharma and biotech companies on 4 - 6 December 2018 in Amsterdam, Cell Therapy Manufacturing & Gene Therapy will provide you with the latest advice for transforming innovative research to prosperous cell & gene therapy manufacturing.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement